StockNews.AI
GNPX
StockNews.AI
181 days

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

1. Genprex partners with CDMO to advance diabetes gene therapy research. 2. Use of non-viral delivery system enhances GNPX's innovation in the diabetes market.

2m saved
Insight
Article

FAQ

Why Bullish?

Strategic collaboration signals innovation potential, similar to GNPX's past collaborations boosting stock prices.

How important is it?

The collaboration positions GNPX strategically within the diabetes market, potentially drawing investment and influencing stock performance.

Why Long Term?

Advancements in gene therapy may take time to translate into market success, akin to previous drug developments which took years.

Related Companies

GNPXXLRNCERS
Researching Novel Diabetes Gene Therapy Using Potentially Re-Dosable Non-Viral Delivery System Strategic Collaboration with CDMO Partner Positions Genprex as a Thought-Leader in Diabetes Market AUSTIN, Texas , Feb. 19, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the advancement of its diabetes program through a strategic collaboration with a contract development and manufacturing organization (CDMO) to research an alternative second generation approach using a non-viral lipid nanoparticle delivery of the Company's diabetes gene therapy drug candidate. "This collaboration with our CDMO partner is separate from our existing preclinical research programs and seeks to evaluate potential next generation construct optimization," said Ryan Confer, President and Chief Executive Officer at Genprex.

Related News